BUFFALO GROVE, Ill., June 19, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Università degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.
"Dr. Festuccia has studied TORC1 and TORC2 inhibition extensively in various cancer models. His work on RES-529 has provided RestorGenex with key compound information that has been integral to our research and development planning. The reported study investigated the role of TORC1 and TORC2 in proliferation and apoptosis induced by hormone manipulation in both androgen sensitive and castration resistant prostate cancer models. In addition, Professor Festuccia and his team evaluated the potential for combination treatment of RES-529 induced TORC1/TORC2 inhibition with hormonal therapy in both in vitro and in vivo models," stated Mark Weinberg, MD, MBA, senior vice president of clinical development for RestorGenex. "We look forward to Professor Festuccia's presentation and conclusions at the close of the Congress."
Stephen M. Simes, chief executive officer of RestorGenex added, "Carcinoma of the prostate is an increasing healthcare problem globally. The need for superior therapeutic regimens and the development of novel treatments to improve the poor outcomes of patients with castration-resistant prostate cancer remains. RestorGenex is encouraged by the ongoing research of RES-529 in various cancer types including prostate cancer, glioblastoma, breast cancer and lung cancer."
About RestorGenex Corporation
RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.
Forward Looking Statements
Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of RES-529 and other statements that are not historical in nature, particularly those that utilize terminology such as "will," "potential," "look forward," "could," "plans," "anticipates," "expects," "may," "future," "continue," "show promise," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause RestorGenex's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular risks and uncertainties include, among others, uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, RestorGenex's ability to license out its existing products and technologies and license in additional products and technologies and the terms of such licenses; and other risks and uncertainties described in RestorGenex's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2015. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex's current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.